Risk Stratification: Uncertain Risk Category
This patient with stage IA, grade 1, no LVSI endometrial carcinoma with TP53 mutation is classified as "Uncertain Risk" according to the latest 2025 ESMO-ESGO-ESTRO-ESP guidelines, and adjuvant therapy is generally not recommended. 1
Understanding the Classification
The 2025 ESMO guidelines explicitly address this specific clinical scenario. The guidelines state that stage IA1m p53abn (p53-abnormal, indicating TP53 mutation) endometrial carcinoma falls into the uncertain risk category 1. This is a newly defined category that acknowledges insufficient data for definitive treatment recommendations.
Why "Uncertain Risk"?
The paradox here is critical to understand:
- TP53 mutations typically confer high-risk biology - In most stage IA cases with deeper invasion (IA2, IA3) or stage IB, p53abn tumors are classified as high-risk 1
- However, in stage IA1 with grade 1 and no LVSI, there are scarce data suggesting the risk of recurrence is "somewhat higher than for low-risk carcinoma" but not definitively high-risk 1
- The low-grade histology (grade 1) conflicts with the aggressive molecular signature, creating clinical uncertainty
Treatment Recommendation
Adjuvant therapy is generally not recommended (Level IV, C evidence) 1
This recommendation is based on:
- Insufficient data to support benefit from adjuvant treatment in this specific subset
- The favorable clinicopathologic features (stage IA1, grade 1, no LVSI) may counterbalance the p53abn status
- Risk of overtreatment given the early stage and favorable histologic features
Critical Caveats
The Grade 1 Designation Matters
Your case specifies grade 1, which is unusual for p53abn tumors. Research shows that p53abn overexpression is significantly associated with grade 3 tumors (23%) and non-endometrioid histology (33%) 2. A grade 1 p53abn tumor is uncommon and warrants:
- Pathology review confirmation - Ensure the grade 1 designation is accurate
- Verification of p53 immunohistochemistry interpretation - Confirm true p53-abnormal pattern (complete loss or diffuse strong overexpression)
- Consider TP53 sequencing if discordant - Grade 1 morphology with p53abn is atypical
Multidisciplinary Discussion Required
While the guideline states "generally not recommended," this is Level IV, C evidence - the weakest recommendation level 1. Therefore:
- Present at tumor board for individualized discussion
- Consider patient age, performance status, and preferences
- If patient is young with excellent performance status, some clinicians may consider adjuvant therapy despite guidelines
Close Surveillance Essential
Given the "somewhat higher" recurrence risk acknowledged in the guidelines 1:
- More frequent follow-up than standard low-risk patients
- Consider imaging surveillance beyond routine protocols
- Low threshold for investigating symptoms
Comparison to Other Risk Categories
To contextualize this classification:
- If this were stage IA2 or IA3 p53abn → High-risk category requiring external beam radiotherapy + chemotherapy 1
- If this were stage IA1 without p53abn → Low-risk category, no adjuvant therapy 1
- The uncertain category sits between these extremes - acknowledging the molecular high-risk feature but recognizing insufficient evidence for aggressive treatment in this specific early-stage, low-grade context
Practical Algorithm
- Confirm pathology: Verify grade 1 and p53abn status with expert pathology review
- If confirmed: Classify as uncertain risk per 2025 ESMO guidelines
- Default approach: No adjuvant therapy (guideline recommendation)
- Consider exceptions: Young age, patient anxiety, or additional unmeasured risk factors may warrant discussion of adjuvant therapy
- Surveillance: Enhanced follow-up compared to standard low-risk protocols
The 2025 guidelines represent a significant evolution in recognizing that molecular classification alone does not override all clinicopathologic features, particularly in very early-stage disease with favorable histology 1, 3.